Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →TechCrunch framed the deal as J&J spending heavily for an 'already-approved' lung cancer diagnostics platform, positioning it among the largest VC-backed…
A Delaware Chancery judge ordered J&J to pay former Auris shareholders more than $1B, finding J&J breached its commercially-reasonable-efforts obligations and…
Delaware Supreme Court (Jan 2026) in J&J v. Fortis Advisors affirmed the fraud finding and breach of contract on most Auris contingent-milestone earnouts, but…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Ethicon (a J&J subsidiary) agreed to acquire Auris Health for approximately $3.4B in cash plus up to $2.35B in contingent milestone payments. Auris's lead platform was the FDA-cleared Monarch robotic bronchoscopy system for lung cancer diagnosis. Acquisition closed April 1, 2019. Post-close, the up-to-$2.35B contingent earnout became the subject of major litigation: in J&J v. Fortis Advisors (Delaware), a Sept 2024 Chancery judgment awarded former Auris shareholders more than $1B, finding J&J committed fraud and breached commercially-reasonable-efforts obligations on the milestone payments; the Delaware Supreme Court (Jan 2026) affirmed the fraud finding and breach on most milestones while reversing the Milestone 1 (lung ablation 510(k)) damages and remanding for interest recalculation. The Monarch platform itself advanced under J&J with FDA 510(k) clearance of the AI-enabled MONARCH QUEST in March 2025 and publication of the 679-patient TARGET study in CHEST in May 2025.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Auris Health, Inc. (this deal) | 2019 | $5.8B | — |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2019 deals · Johnson & Johnson deals · Oncology deals